Publications by authors named "A Klion"
Background: Hypereosinophilic syndromes (HES) are defined as hypereosinophilia with eosinophil-related clinical manifestations, some of which overlap in presentation with asthma, atopic dermatitis, eosinophilic esophagitis, and/or chronic rhinosinusitis with nasal polyps. Dupilumab is approved to treat these conditions but can induce a transient rise in the absolute eosinophil count and rare eosinophil-related complications.
Objective: To determine whether eosinophil-related complications of dupilumab are increased in HES.
Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis.
Immunol Allergy Clin North Am
November 2024
Article Synopsis
- Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are disorders characterized by high levels of eosinophils in the blood and tissues, leading to varied symptoms.
- Traditionally, treatment has relied on systemic glucocorticoids; however, new biologic therapies targeting eosinophils offer alternatives that could lead to better results with fewer side effects.
- The article reviews the evidence for using these biologics in treating HES and EGPA and outlines how they can be effectively employed in patient care.
The Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR) and The International Gastrointestinal Eosinophil Researchers (TIGERs) organized a daylong symposium at the 2024 annual meeting of the American Academy of Allergy, Asthma & Immunology. The symposium featured new discoveries in basic and translational research as well as debates on the mechanisms and management of eosinophilic gastrointestinal diseases. Updates on recent clinical trials and consensus guidelines were also presented.
View Article and Find Full Text PDF